Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics, Inc. (LENZ) Total Non-Current Liabilities (2022 - 2023)

LENZ Therapeutics (LENZ) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $62.2 million as the latest value for Q3 2023.

  • On a quarterly basis, Total Non-Current Liabilities rose 289.41% to $62.2 million in Q3 2023 year-over-year; TTM through Sep 2023 was $62.2 million, a 289.41% increase, with the full-year FY2022 number at $14.8 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $62.2 million for Q3 2023 at LENZ Therapeutics, down from $62.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $62.9 million in Q2 2023 to a low of $14.8 million in Q4 2022.